by Molly Walker, Deputy Managing Editor, MedPage Today April 28, 2022 The FDA gave the green light to oteseconazole (Vivjoa), making it the first approved medication to treat chronic yeast infections, manufacturer Mycovia Pharmaceuticals announced on Thursday. Due to embryo-fetal toxicity risks, however, the oral drug is indicated for recurrent vulvovaginal candidiasis (RVVC) only in women who...
